Merck strengthens commitment to Chinese growth market

Merck KGaAMerck, a leading company for high-tech products in the pharmaceutical and chemical sectors, today reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its emerging markets growth strategy.

Merck's Executive Board this week met in Shanghai, a month before the groundbreaking of its new pharmaceutical plant in Nantong, which from 2017 will be the Group's second-largest pharmaceutical manufacturing facility globally. Merck currently employs more than 2,000 people at over 40 sites in China, with the most important products including Erbitux to treat cancer, Gonal-f to treat infertility as well as life science tools and liquid crystals (LC) for flat panel displays. In total, Merck has committed more than € 100 million to investments in China over that past three years.

"China is of strategic importance to Merck," said Karl-Ludwig Kley, Chairman of the Executive Board." Together with government officials, customers, partners and our highly motivated local colleagues, we will explore ways to further address critical health care needs of the Chinese population - both with our high-quality drugs and our life science tools for biopharmaceutical R&D. We're also meeting with customers in the display industry to continue our constant dialogue about innovative solutions to meet the needs of the ever-changing high -tech market."

Merck has a strong presence in the fast-growing emerging markets: Sales in the region, which includes China, grew by 9% to around €3.8 billion last year, contributing 36% to Group total sales of €10.7 billion in 2013.

At a press conference in Shanghai today, Kley said the Group's newly built Liquid Crystals Center China, based in the Jinqiao Industrial Park in Shanghai, started delivering its first products to Chinese customers in the second quarter. Trial production at the center, which integrates a liquid crystal mixing plant, an LC lab and the China LC business hub, started in December 2013.

Adding another premium specialty chemicals business to Merck's existing LC business and further expanding its presence in the Asian market, Merck earlier this year bought AZ Electronic Materials (AZ), a leading solutions provider of high-tech materials and functional specialty chemicals. AZ has a site in the Greater Shanghai region in Suzhou and employs nearly 100 people in China.

Next month, groundbreaking is planned for Merck's new €80 million (650 million Yuan) pharmaceutical manufacturing plant in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area). Completion of the facility, which will focus on bulk production and packaging of Glucophage, Concor and Euthyrox, is scheduled for 2016, with commercial production starting in 2017. Merck's brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders are referenced in China's Essential Drug List (EDL), making Merck the first and only multinational company in China to dedicate a large scale green-field investment towards the production of drugs on the list comprising medicines that satisfy public healthcare needs and must be made available at all times.

In addition to investments in drug production, Merck has also expanded its services for biopharmaceutical research and development customers. Recent investments by the Merck Millipore life science tools business include the Biopharmaceutical Technical and Training Centre in Zhangjiang Hi-Tech Park, Shanghai. This center provides support, training and validation services to biopharmaceuticals customers with operations in China. The facility enables customers to investigate, explore and optimize their upstream and downstream processes as well as environmental monitoring processes. In Beijing, where Merck Serono's Chinese headquarters are located, Merck also runs a research center focused on biomarker research, including pharmacogenomics and bioanalytics, which is part of Merck Serono's stratified medicine approach.

In addition to these investments, Merck counts on an extensive network of collaborations with leading academic and medical institutions in China, as well as local companies. The latest collaboration agreement with a Chinese company, announced in November 2013, is a second co-development and commercialization agreement with BeiGene, which will further strengthen the companies' collaboration in oncology.

About Merck KGaA
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of €11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...